Cizzle Biotechnology Share Discussion Threads

[secretsqu] 16/11/2023 20:37

I was assuming his meaning was attracting big hitters needed 3p.

[oapknob1] 16/11/2023 20:23

22 February 2023TR-1: Standard form for notification of major holdingsThink some got in a while ago

[secretsqu] 16/11/2023 20:07

"This needs to be above 3p to convince the big hitters for SIX "?The price of the share price is immaterial unless you're a day trader.The big hitters (who are they btw) are waiting for the breakout announcement... clinical trial results.LTHs are here for the outcome of the clinical trial, not the daily share price movements.You won't be concerning yourself with any figure in the low double digits, let alone 3p.Dyor

[secretsqu] 16/11/2023 19:54

Not a single LTH has stated that, so why even bother posting the utter diatribe that is posted on the X twitter cesspool.

[thehitman1] 16/11/2023 12:44

Great company.

[oapknob1] 16/11/2023 12:39

https://www.nysenate.gov/legislation/bills/2023/S1196/amendment/A#:~:text=2023%2DS1196A%20(ACTIVE)%20%2D,by%20medical%20and%20scientific%20evidence

[oapknob1] 16/11/2023 12:20

The Facility has been extended until 8 December 2024 and will be drawable in tranches of not less than GBP100,000 as requested by the Company or the Investor. The first drawdown will be made available to the Company following Shareholder Approval at the Company's next General Meeting to allot a further 23,809,524 new Ordinary Shares. Repayment of the Facility is to be by way of issue and allotment of new Ordinary Shares in the capital of the Company at a new fixed price equal to the Issue Price of 2.1p per share ("Facility Shares").

[jimduggen] 16/11/2023 12:17

Costs are covered for trials from partners.
Read the historical rns releases you moron

[secretsqu] 16/11/2023 10:55

You should try some research.

[secretsqu] 16/11/2023 09:21

What funding?

[secretsqu] 16/11/2023 08:25

From neilin over on the other channel...News from US 21 hours agoToday 00:14News from USA 21 hours ago is that New York is in the final stage of implementing into law, requirement for biomarker testing for cancer detection. Final stage is for Governor Kathy Hochul to sign Senate Bill 1196a/Assembly Bill 1673a into law. This bill will require all state regulated health plans in New York including Medicaid, to cover comprehensive biomarker testing for millions of residents. Millions - and that's just in the state of New York. Medicare should be very interested in this since a study shows that patients that received broad panel biomarker testing and subsequent targeted treatment saved around $8,500 a MONTH in total care cost compared to those receiving narrow panel biomarker testing. Something i posted previously about our biomarker being used for targeted treatment - i knew it was of importance alongside the actual diagnostic part of the test, but i didn't quite realise just HOW MUCH the importance this part of the CIZ1b story is. Once a patient has been diagnosed with cancer, that isn't the end of the test. i.e it's not just a one time thing. As well as being invaluable in developing and identifying drug / therapy treatments targeted at specific cancers, apparently, it is just as important to carry out repeat tests during treatment in order to observe any changes in the cancer, or resistance to treatment, so adjustments can be made accordingly. So repeat revenue stream in addition to the initial test. Neil